{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"80-89% necrosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"90-99% necrosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"100% necrosis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The count of participants with greater than or equal to 80% pathological necrosis in the resected specimen following neoadjuvant bevacizumab and radiation.","groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"OG000","title":"Bevacizumab, Radiation, and Surgery"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Objective Response Rate for Neoadjuvant Bevacizumab Combined With Radiation Therapy for Intermediate and High-risk Soft Tissue Sarcomas.","type":"PRIMARY","unitOfMeasure":"participants"}